• Cancer is the leading cause of death in Australia, with about 1 in 2 Australian men and 1 in 3 Australian women will be diagnosed with cancer in their life.
  • Clinical trials play an essential role in discovering new and more effective treatments for cancer.
  • Outstanding research-based health care is provided to all participants involved in clinical trials and we offer comprehensive and integrated evidence-based treatment options.
  • Gynaecological Cancers
  • Breast Cancer
  • Pancreatic/Upper Gastrointestinal Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Brain Cancer
  • Melanoma
Head of Department, Cancer Services
Dr Andrew Dean

Head of Palliative Care Services
Dr Derek Eng

Medical Registrar
Dr Meabh McNulty, Dr Dom Higgs

Project Manager – Clinical Trials Development
Dr Jo Youd

Research Data Scientist
Andrew Mews

Please see Oncology Clinical Trial Unit for all other key staff
Das, A., Dean, A., Clay T. Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma. (2019) BMJ Case Reports CP 12:e228363

Travers, N., Cronin, E., Marinova, M., Smith, P., Dean, A.P. Anaplastic thyroid cancer: A report of six consecutive cases treated successfully with nab-paclitaxel (2019) Journal of Clinical Oncology 2019 37:15_suppl, e17586-e17586

Dean, A.P., Das, A., McNulty, M., Higgs, D. Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma. Journal of Clinical Oncology 37, 2019 (suppl; abstract e15794)
Shaughnessy, E., Armstrong, K., Rogers-Seeley, M., Das, A., Higgs, D., Dean, A.P. Pneumocystis jiroveci pneumonia during first and second-line chemotherapy for solid tumours. Journal of Clinical Oncology 2019 37:15_suppl, e18330-e18330

Rogers, P., Jones, C., Dean, A
. A rare skin condition masquerading as a serious wound infection J Surg Case Rep. 2018 Nov; 2018(11): rjy299.

McNulty, M., Dean, A., Das, A., Gordon, M. Use of gemcitabine and nab-paclitaxel as a third-line treatment following failure of first-line gemcitabine for advanced pancreatic adenocarcinoma. Annals of Oncology 29, no. suppl_5 (2018): mdy151-146.

Hardcastle, S. J., Kane, R., Chivers, P., Hince, D., Dean, A., Higgs, D., Cohen, P.A. Knowledge, attitudes, and practice of oncologists and oncology health care providers in promoting physical activity to cancer survivors: an international survey. Support Care Cancer. 2018 Nov; 26(11) :3711-3719.

Dean, AP., Higgs, D., Robins, P., Stobie, P., Craven, P., Daly, C., Carija, S. Use of FDG PET scanning to evaluate 5-FU myocardial toxicity as a global metabolic effect rather than vascular spasm. Journal of Clinical Oncology 36, no. 4_suppl (February 1 2018) 792-792

Aghajanian, C., Coleman, R.L, Oza, A.M., Lorusso, D., Oaknin, A., Dean, A.P., Colombo, N. et al. Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study. Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 5537-5537

You may be interested in